Key Market Indicators
Sales of antihypertensive medicine in Latvia are expected to reach $5.3 million by 2026, growing at an average annual rate of 1.9%. This is up from $4.84 million in 2021, when Latvia ranked 19th in the world for antihypertensive drug sales. Since 2006, Latvian demand for antihypertensive medicine has increased by an average of 4.4% per year. Denmark led the way in 2021, with sales of $4.84 million. Italy, Spain, and Australia placed second, third and fourth, respectively.
